Saturday 17 October 2026
Export ACTU’s income statement to Excel — free account
Actuate Therapeutics, Inc.
ACTU Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.3% and free cash flow fell 5.54%, each against the same quarter a year earlier.
0.61
0.11
+22.00%
Follow ACTU
Actuate Therapeutics, Inc. (ACTU) P/E ratio
Actuate Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 6.5× (May 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 6.5×
Ten-year median
0.0×
Current reading's percentile
65
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACTU Actuate Therapeutics, Inc. | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| PTN Palatin Technologies, Inc. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | n/m |
| INAB IN8bio, Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| ASBP Aspire-Lakewood Holdings, Inc. compare | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)